Literature DB >> 2007170

Hypercholesterolemia in long-term survivors of heart transplantation: an early marker of accelerated coronary artery disease.

D Eich1, J A Thompson, D J Ko, A Hastillo, R Lower, S Katz, M Katz, M L Hess.   

Abstract

Coronary artery disease remains a significant long-term problem for survival after heart transplantation. Hyperlipidemia is a known risk factor for coronary artery disease in the general population, but the role of hyperlipidemia in cardiac allograft recipients has not been elucidated. To study this problem, we retrospectively reviewed 38 heart transplant recipients who survived more than 3 years after surgery and looked at age, development of diabetes, drug protocol, and development of hypercholesterolemia for a possible correlative or predictive value to the development of early coronary artery disease after heart transplantation. Eleven patients were identified as having coronary disease by the third year after transplantation. High-risk cholesterol values (in milligrams per deciliter) at 6 months after heart transplantation were defined as follows: for ages 10 to 20, 190; 20 to 30, 220; 30 to 40, 240; 40+, 260. We found a strong predictive value with high-risk lipid profiles (p less than 0.01) for the development of coronary artery disease by the third year. No significance was found for a low-risk value, the development of diabetes, or hypertension. All patients below the age of 20 years had coronary artery disease by the third year after transplantation. We conclude that a high-risk cholesterol value at 6 months after transplantation is a strong predictor for development of accelerated coronary artery disease and early graft failure. This has major implications for management of hyperlipidemia in the cardiac allograft recipient.

Entities:  

Mesh:

Year:  1991        PMID: 2007170

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  12 in total

1.  Graft vascular disease in heart transplant patients.

Authors:  J Mann
Journal:  Br Heart J       Date:  1992-09

2.  Simvastatin after orthotopic heart transplantation. Costs and consequences.

Authors:  K J Krobot; K Wenke; B Reichart
Journal:  Pharmacoeconomics       Date:  1999-03       Impact factor: 4.981

3.  Accelerated graft atherosclerosis after heart transplantation.

Authors:  S C Grant; N H Brooks
Journal:  Br Heart J       Date:  1993-05

4.  First-year clinical outcomes in gender-mismatched heart transplant recipients.

Authors:  Anne Jalowiec; Kathleen L Grady; Connie White-Williams
Journal:  J Cardiovasc Nurs       Date:  2012 Nov-Dec       Impact factor: 2.083

Review 5.  The pathophysiology of Sandimmune (cyclosporine) in man and animals.

Authors:  J Mason
Journal:  Pediatr Nephrol       Date:  1990-11       Impact factor: 3.714

Review 6.  The metabolic effects of cyclosporin and tacrolimus.

Authors:  P Marchetti; R Navalesi
Journal:  J Endocrinol Invest       Date:  2000 Jul-Aug       Impact factor: 4.256

Review 7.  Acceleration of allograft failure by cytomegalovirus.

Authors:  Daniel N Streblow; Susan L Orloff; Jay A Nelson
Journal:  Curr Opin Immunol       Date:  2007-08-22       Impact factor: 7.486

8.  Smooth muscle cells of the coronary arterial tunica media express tumor necrosis factor-alpha and proliferate during acute rejection of rabbit cardiac allografts.

Authors:  H Tanaka; S J Swanson; G Sukhova; F J Schoen; P Libby
Journal:  Am J Pathol       Date:  1995-09       Impact factor: 4.307

Review 9.  Graft vessel disease following heart transplantation: a systematic review of the role of statin therapy.

Authors:  Robin Som; Peter J Morris; Simon R Knight
Journal:  World J Surg       Date:  2014-09       Impact factor: 3.352

Review 10.  Endothelial dysfunction and cardiac allograft vasculopathy.

Authors:  Monica Colvin-Adams; Nonyelum Harcourt; Daniel Duprez
Journal:  J Cardiovasc Transl Res       Date:  2012-11-08       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.